"This Phase 3 clinical trial will use a primary endpoint that comprises both pain relief and improved function, consisting of a 50% reduction in lower back pain as measured by Visual Analog Score and a 15-point improvement in Oswestry Disability Index, with no additional interventions."
This 50% reduction in pain seems very ambitious. I wish they had kept it to a meaningful reduction in pain, like all other pain trials which means a 20% reduction in pain as measured by VAS.
I wonder what their phase two results and p value were.
News 
Market Data 
Discover 
